Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (
A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi
BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside
After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product.
After a setback in a trial of Imfinzi in early non-small cell lung cancer (NSCLC) last year, AstraZeneca has clawed back some ground with a positive result in small-cell l
Australian radiopharma developer Telix Pharma and US neuroscience specialist Rapport Therapeutics have become the latest biotechs to weigh in for initial public offerings
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.